Lenalidomide G.L.

Lenalidomide, the active ingredient in Lenalidomide G.L., is an immunomodulatory agent presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide G.L. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance.

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting disease pathways that drive cancer cell growth.

- Multiple Myeloma: improves progression‑free and overall survival in adult patients. - Myelodysplastic Syndromes (del(5q)): reduces transfusion dependence and may achieve cytogenetic remission. - Mantle Cell Lymphoma (in combination therapy): enhances response rates when added to standard regimens.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may require hydration. - Constipation: reduced bowel movements. - Rash: skin irritation or erythema. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia or anemia: marked reduction in blood cell counts. - Infections: opportunistic or serious bacterial infections. - Second primary malignancies: emergence of new cancers. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before initiating therapy, clinicians should assess patient risk factors and monitor laboratory parameters regularly. - Pregnancy: contraindicated; avoid use in pregnant women and ensure effective contraception. - Thrombosis risk: evaluate history and consider prophylactic anticoagulation when indicated. - Hematologic monitoring: perform frequent CBCs to detect neutropenia, anemia, or thrombocytopenia. - Renal impairment: adjust dose or increase monitoring in patients with reduced kidney function. - Drug interactions: review concomitant medications for potential CYP3A4 or P‑gp interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding complications. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil, amiodarone): can raise drug levels. - Other immunomodulatory agents (e.g., thalidomide, pomalidomide): additive myelosuppression risk.